NRAS Gene - GeneCards | RASN Protein | RASN Antibody

GeneCards Symbol: NRAS · 2 ; NRAS Proto-Oncogene, GTPase · 235 ; N-Ras · 235 ; Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog · 23 ; Neuroblastoma RAS Viral Oncogene Homolog · 23 ; Transforming Protein N-Ras · 34 ; GTPase NRas · 34 ; V-Ras Neuroblastoma RAS Viral Oncogene Homolog · 3 ; Proto-Oncogene GTPase · 3

NAVER 학술정보 > Data from BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load C

초록 AbstractPurpose: The mutation load in melanoma is generally high compared with other... Differences between categories solar elastosis, pigmentation, BRAF/NRAS mutational status...

(PDF) Novel insights into the pathogenesis and treatment of NRAS mutant melanoma - ResearchGate

PDF | Introduction: NRAS was the first mutated oncogene identified in melanoma and is currently the second most common driver mutation in this... | Find, read and cite all the research you need on...

Vemurafenib Therapy and BRAF and NRAS Genotype - Medical Genetics Summaries - NC - 미국 국립생물정보센터

Vemurafenib is a kinase inhibitor used in the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E variant. BRAF is an intracellular kinase in the mitogen-activated protein kinases (MAPK) pathway. BRAF is involved in regulating important cell functions such as cell growth, division, differentiation, and apoptosis. BRAF is also a proto-oncogene—when mutated it has the ability to transform normal cells into cancerous cells. Variation in the kinase domain of BRAF have been associated with various cancers. The most c ...

OSUMMER.13 Mouse NRAS-Mutant Melanoma Cell Line

OSUMMER.13 Mouse NRAS-Mutant Melanoma Cell Line; Synonyms: Mouse melanoma cell line; find Sigma-Aldrich-SCC457 MSDS, related peer-reviewed papers, technical documents, similar products & more at Si...

[논문]Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanom - 과학기술 지식인프라 ....

Summary Background There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binim...

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networ

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. by Inna V Fedorenko, Bin Fang, Ana Cecelia Munko, Geoffrey T Gibney, John M Koom...

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiatio

We generate eight conditional, knock-in mouse models and show that rare melanoma mutants (NRAS G12D, G13D, G13R, Q61H, and Q61P) are poor drivers of spontaneous melanoma formation, whereas...

[논문]Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale - 과학기술 지식인프라 S....

Background: Mutations of NRAS and BRAF have been described in Caucasian melanomas. However, the status and the clinical significance of BRAF and NRAS mutations in the Asian population have not been...

[논문]Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melano - 과학기술 지식인프라 ....

Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma The Journal of investigative dermatology, v.126 no.1, 2006년, pp.154 - 160 Goel, Vikas K. , Lazar, Alexander J....